Trials
Search / Trial NCT06435884

Long-Term Follow-up of Adult With Atorpphic Scars Treated With TRTP-101

Launched by CELLINCELLS · May 24, 2024

Apply for Trial

Trial Information

Current as of March 14, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, titled "Long-Term Follow-up of Adults With Atrophic Scars Treated With TRTP-101," is studying the long-term safety and effectiveness of a treatment called TRTP-101 for people with atrophic scars, which are indented scars that can occur after injury or surgery. The study is currently recruiting participants who have previously received TRTP-101 in a related clinical trial and are willing to provide written consent to be part of this follow-up study.

Eligible participants are adults aged 39 and older who have already been treated with TRTP-101 and agree to continue their involvement in this long-term study. Those who are considered unsuitable for participation will not be included. If you decide to take part, you can expect regular check-ins to monitor your health and how well the treatment is working over time. This trial is important as it aims to provide valuable information about how TRTP-101 works in the long run, helping to improve treatments for atrophic scars in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Received TRTP-101 in clinical trial CIC101-01
  • • Provided written informed consent to participate in this study
  • Exclusion Criteria:
  • • Judged to be unsuitable to participate in this long-term follow-up

Trial Officials

JongHee Lee, MD

Principal Investigator

Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine

About Cellincells

Cellincells is a pioneering biopharmaceutical company dedicated to advancing innovative cell-based therapies for the treatment of various diseases. With a strong emphasis on research and development, Cellincells leverages cutting-edge technology and a robust pipeline to create transformative solutions that address unmet medical needs. The company is committed to rigorous clinical trials and regulatory standards, ensuring the safety and efficacy of its products. By fostering collaborations with academic institutions and industry partners, Cellincells aims to accelerate the translation of scientific discoveries into impactful therapies, ultimately improving patient outcomes and enhancing quality of life.

Locations

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0